Clinical Trial

Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor

Name: Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor — clinical trial record (NCT07743554)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: NF120

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to learn whether the study drugs avutometinib and defactinib can help stop or shrink malignant peripheral nerve sheath tumors (MPNST) that have returned or cannot be removed with surgery.

Trial Details

NCT Number	NCT07743554
Lead Sponsor	Girish Dhall, MD Collaborators: United States Department of Defense, Children's Hospital of Philadelphia, Washington University School of Medicine
Conditions	MPNST (Malignant Peripheral Nerve Sheath Tumor)
Enrollment	23 participants
Start Date	2027-01-01
Primary Completion	2031-01 (estimated)
Study Completion	2032-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-04